Tabimorelin
Tabimorelin did not show beneficial effects on GH release in adult patients with GHD in a Phase II study [17]. Also, tabimorelin has been reported to inhibit CYP3A4, which can lead to unexpected side effects [18]. To overcome this disadvantage, Novo Nordisk has developed some compounds derived from tabimorelin, such as NNC-26-1167, although they have not yet been evaluated in clinical trials.